Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Osteogenesis imperfecta.

Joan C Marini1, Antonella Forlino2, Hans Peter Bächinger3

  • 1Section on Heritable Disorders of Bone and Extracellular Matrix, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Building 49, Rm 5A42, 9000 Rockville Pike, Bethesda, Maryland 20892, USA.

Nature Reviews. Disease Primers
|August 19, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Establishing a Zebrafish Functional Assay to Assess the Pathogenicity of Variants of Uncertain Significance in Ciliopathies.

European journal of clinical investigation·2026
Same author

Collagen hybridizing peptide to target in vivo misfolded collagen in OI zebrafish.

Scientific reports·2026
Same author

Impact of oxygen-ozone mixture on cellular functions: a biochemical perspective across cell types.

Molecular medicine (Cambridge, Mass.)·2026
Same author

OMICS Profiling Identifies Signatures of Senescence in Osteogenesis Imperfecta Osteoblasts Counteracted by 4-PBA.

Journal of cellular and molecular medicine·2026
Same author

Infectious seeds of valve calcification: Exploring the bacterial hypothesis in the pathogenesis of calcific aortic valve disease.

European journal of clinical investigation·2026
Same author

Inhibition of FGFR signaling with infigratinib improves linear bone growth in the female <i>Aga2/+</i> mouse model of osteogenesis imperfecta.

JBMR plus·2026
This summary is machine-generated.

Osteogenesis imperfecta (brittle bone disease) causes bone fragility due to collagen defects. Recent discoveries reveal numerous genetic causes beyond collagen, complicating classification and treatment.

Area of Science:

  • Genetics
  • Molecular Biology
  • Orthopedics

Background:

  • Osteogenesis imperfecta (OI) is a brittle bone dysplasia characterized by skeletal deformity and bone fragility.
  • Diagnosis typically relies on clinical presentation and family history, with genetic testing confirming the condition.
  • Mutations in type I collagen genes (COL1A1, COL1A2) cause ~85% of OI cases, affecting collagen quantity or structure.

Purpose of the Study:

  • To review the genetic basis of osteogenesis imperfecta.
  • To discuss the expanding spectrum of causative genes and their impact on classification.
  • To highlight the diverse clinical manifestations and current/emerging therapeutic strategies for OI.

Main Methods:

  • Literature review of genetic causes of osteogenesis imperfecta.

Related Experiment Videos

  • Analysis of clinical and genetic classifications of OI.
  • Summary of current management and future therapeutic avenues.

    • Main Results:

    • While COL1A1/COL1A2 mutations are common, numerous other genes involved in collagen processing and bone cell regulation are now known to cause OI.
    • The identification of many causative genes has led to a complex genetic classification system, still under debate.
    • OI presents with extraskeletal manifestations including cardiovascular, pulmonary, skin, muscle, hearing, and dental issues.

    Conclusions:

    • Osteogenesis imperfecta is genetically heterogeneous, with numerous genes implicated beyond type I collagen.
    • The expanding genetic landscape complicates OI classification but underscores the need for personalized treatment approaches.
    • Current management focuses on skeletal and extraskeletal complications, with gene therapy and cell-based approaches under investigation.